References
- WilliamsJPMeyersJAImmune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costsAm J Manag Care20028S664S68112516953
- KuekAHazlemanBLOstorAJImmune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgrad Med J20078325126017403952
- CarterPHZhaoQClinically validated approaches to the treatment of autoimmune diseasesExpert Opin Inv Drugs201019195213
- LichtensteinGRHanauerSBSandbornWJPractice Parameters Committee of American College of GastroenterologyManagement of Crohn’s disease in adultsAm J Gastroenterol200910446548319174807
- MurphyGReichKIn touch with psoriasis: topical treatments and current guidelinesJ Eur Acad Dermatol Venereol201125Suppl 43821507077
- MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol20085882685018423260
- SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease- modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)20126462563922473917
- ScarpatoSAntivalleMFavalliEGPatient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)Rheumatology (Oxford)20104928929419920093
- VavrickaSRBenteleNScharlMSystematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)Inflamm Bowel Dis2012181523153021987429
- AllenPBLindsayHThamTCHow do patients with inflammatory bowel disease want their biological therapy administered?BMC Gastroenterol201010120064220
- WolfeFMichaudKResistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choicesArthritis Rheum2007562135214217599730